NEW YORK, February 7, 2017 /PRNewswire/ --
This morning, Stock-Callers.com takes note of the performances of thesemajor Drug Manufacturers stocks: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and Immune Pharmaceuticals Inc. (NASDAQ: IMNP). These companies belong to the Healthcare sector which improved slightly
New York headquartered Bristol-Myers Squibb Co.'s shares gained 0.51%, closing Monday's trading session at $51.04. The stock recorded a trading volume of 8.21 million shares. Shares of the Company have advanced 2.32% in the previous three months. The stock is trading 8.09% below its 50-day moving average. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 43.13.
On February 02nd, 2017, Bristol-Myers Squibb announced the US Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Bristol-Myers stated that in the CheckMate -275 trial, 19.6% of patients responded to treatment with Opdivo. See our free and comprehensive research report on BMY at:
On Monday, shares in UK headquartered AstraZeneca PLC recorded a trading volume of 6.30 million shares. The stock rose 0.61%, ending the day at $28.09. The Company's shares have advanced 1.26% in the previous three months and 2.82% on an YTD basis. The stock is trading above its 50-day moving average by 2.96%. Furthermore, shares of AstraZeneca, which engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide, have an RSI of 58.43.
On January 26th, 2017, AstraZeneca announced that the US FDA granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. The FDA's decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a Written Request (a prerequisite for qualifying for paediatric exclusivity under Section 505A of the Federal Food, Drug, and Cosmetic Act). Symbicort is currently approved in the US to treat asthma in patients 12 years and older and for the maintenance treatment of Chronic Obstructive Pulmonary Disease in adults. AZN free research report PDF is just a click away at:
Indiana headquartered Eli Lilly and Co.'s stock finished the day 0.78% higher at $77.83 with a total trading volume of 2.81 million shares. The Company's shares have gained 2.96% in the last one month, 8.64% over the previous three months, and 5.82% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.72% and 2.29%, respectively. Additionally, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 65.68.
On February 02nd, 2017, Eli Lilly announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in Lilly's favor in the invalidation trials initiated by Sawai regarding Lilly's vitamin regimen patents for Alimta. In Q4 2015, the Japan Patent Office issued written decisions upholding the validity of the Alimta vitamin regimen patents. The Company stated that if the patents are ultimately upheld through all challenges, they could provide intellectual property protection for Alimta in Japan until June 2021. Lilly stated that it will take necessary actions to defend and enforce the patents. Sign up for your complimentary report on LLY at:
Shares in New York headquartered Immune Pharmaceuticals Inc. ended yesterday's session 2.59% lower at $0.19. The stock recorded a trading volume of 2.96 million shares. The Company's shares have advanced 3.30% on an YTD basis. The stock is trading 2.88% below its 50-day moving average. Moreover, shares of Immune Pharma, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have an RSI of 41.24.
On January 27th, 2017, Immune Pharma announced that it has appointed Ranch C. Kimball, as Chairman of its Board of Directors. Mr. Kimball's appointment brings a substantial wealth of experience which he will leverage to strategically raise Immune Pharma's profile for its recent re-organization. Register for free on Stock-Callers.com and download the latest research report on IMNP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All